KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTEBusiness Wire • 02/19/24
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value RightGlobeNewsWire • 02/16/24
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® AcquisitionGlobeNewsWire • 01/18/24
FDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRxGlobeNewsWire • 01/11/24
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of DirectorsGlobeNewsWire • 01/08/24
XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® RoyaltiesGlobeNewsWire • 12/19/23
XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder ValueGlobeNewsWire • 11/07/23
XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One's Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)GlobeNewsWire • 10/31/23
XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization StrategyGlobeNewsWire • 08/08/23
XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology AssetGlobeNewsWire • 06/22/23
LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA CorporationBusiness Wire • 06/22/23
XOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization StrategyGlobeNewsWire • 05/09/23
XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone PortfolioGlobeNewsWire • 03/30/23
XOMA Reports Full-Year 2022 Financial Results and Provides Update to the Acceleration of its Differentiated Royalty Monetization StrategyGlobeNewsWire • 03/09/23
XOMA Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 01/07/23
New Executive Leadership Team Appointed to Accelerate XOMA's Differentiated Royalty Monetization StrategyGlobeNewsWire • 01/04/23
XOMA Acquires Royalty and Milestone License to Ebopiprant, a Preterm Labor Asset, Being Developed by OrganonGlobeNewsWire • 11/22/22